(OTCBB:NRGX) Neurologix, Inc

Turning Pennies into dollars: (OTCBB:NRGX) Neurologix, Inc

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147

For more info: http://www.realpennies.com/otc/nrgx

Neurologix to Present at Roth Capital Partners 2008 OC Growth Conference

(OTCBB:NRGX) Neurologix, Inc.

Neurologix to Present at Roth Capital Partners 2008 OC Growth Conference

Monday February 9, 8:00 am ET

- Presentation to be Web Cast on February 16, 2009 -

FORT LEE, N.J.-Neurologix, Inc. , a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced recently that John Mordock, the company?s Chief Executive Officer, will present at the Roth Capital Partners?, 21th Annual OC Conference. The conference will be held February 16-18 at The Ritz Carlton Laguna Niguel in Dana Point, CA.

Mr. Mordock will be making his presentation on February 16 at 2:20 PM Pacific Time. The presentation will be broadcast live on the internet at http://www.wsw.com/webcast/roth20/nrgx/

Founded in 1984, Roth Capital Partners, LLC is an independent investment bank dedicated to emerging growth companies in the small and micro-cap market. For more information about the conference, see http://www.roth.com/main/Page.aspx?PageID=7214

About Neurologix

Neurologix, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system . Neurologix?s therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. Current programs of the company address such conditions as Parkinson?s disease, epilepsy and Huntington?s chorea, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.

Contact:

Neurologix, Inc. Marc Panoff, 201-592-6451 Chief Financial Officer, Treasurer and Secretary marcpanoff@neurologix.net or Kureczka/Martin Associates Media: Joan Kureczka, 415-821 2413 jkureczka@comcast.net Source: Neurologix, Inc.

Profile for Neurologix, Inc.

Neurologix, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and Central Nervous System. The company’s treatments are designed as alternatives to conventional surgical and pharmacological treatments. It focuses on gene therapy for treating Parkinson’s disease, a neurodegenerative disorder; and epilepsy, a group of diseases associated with recurrent seizures, which is caused by periodic episodes of repetitive, abnormal electrochemical disturbance in the central nervous system, beginning in the brain. The company also focuses on the treatment of other neurodegen... Detailed NRGX Company Description...

LAST $0.50 USD

Find out more about NRGX

Realpennies.com

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on

http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com